- Home
- DRCT vs SLGL Comparison
DRCT vs SLGL Comparison
Compare DRCT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- SLGL
- Stock Information
- Founded
- DRCT 2018
- SLGL 1997
- Country
- DRCT United States
- SLGL Israel
- Employees
- DRCT N/A
- SLGL N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- SLGL Health Care
- Exchange
- DRCT Nasdaq
- SLGL Nasdaq
- Market Cap
- DRCT 16.7M
- SLGL 19.3M
- IPO Year
- DRCT 2022
- SLGL 2018
- Fundamental
- Price
- DRCT $0.53
- SLGL $12.48
- Analyst Decision
- DRCT Strong Buy
- SLGL Buy
- Analyst Count
- DRCT 1
- SLGL 1
- Target Price
- DRCT $6.00
- SLGL $40.00
- AVG Volume (30 Days)
- DRCT 155.6K
- SLGL 11.4K
- Earning Date
- DRCT 05-06-2025
- SLGL 08-15-2025
- Dividend Yield
- DRCT N/A
- SLGL N/A
- EPS Growth
- DRCT N/A
- SLGL N/A
- EPS
- DRCT N/A
- SLGL N/A
- Revenue
- DRCT $48,170,000.00
- SLGL $12,103,000.00
- Revenue This Year
- DRCT $50.71
- SLGL N/A
- Revenue Next Year
- DRCT $26.31
- SLGL $31.17
- P/E Ratio
- DRCT N/A
- SLGL N/A
- Revenue Growth
- DRCT N/A
- SLGL 603.66
- 52 Week Low
- DRCT $0.44
- SLGL $3.34
- 52 Week High
- DRCT $6.59
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- DRCT 44.72
- SLGL 85.60
- Support Level
- DRCT $0.50
- SLGL $10.77
- Resistance Level
- DRCT $0.57
- SLGL $12.90
- Average True Range (ATR)
- DRCT 0.05
- SLGL 0.92
- MACD
- DRCT -0.00
- SLGL 0.43
- Stochastic Oscillator
- DRCT 24.59
- SLGL 92.05
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.